Untitled

Loading Events

« All Webinars

To Use or Not to Use Liposomal Bupivacaine: Managing Pharmacotherapy Costs in Orthopaedic Procedure Pain Management

HealthTrust presents

To Use or Not to Use: Liposomal Bupivacaine: Managing Pharmacotherapy Costs in Orthopaedic Procedure Pain Management

Liposomal bupivacaine (LB) was approved in 2011 for the indication of surgical site administration to produce postsurgical analgesia. As a sustained-release formulation of bupivacaine HCI, LB was thought to provide postsurgical pain relief for up to 72 hours. Recent clinical trials have demonstrated that the use of LB is not superior compared to conventional pain management but rather more costly. In this program, literature on LB use in orthopedic procedures will be reviewed. The findings of a health economic study of LB at Community Health Systems (CHS) and CHS’s experience and strategy in minimizing LB use will be discussed, including CHS’s approach to managing the pharmacotherapy costs of pain management for orthopedic procedures.

Learning Objectives

  1. Discuss the current literature on the efficacy and safety of liposomal bupivacaine in orthopedic procedures
  2. Describe the findings of an enterprise-wide liposomal bupivacaine health economic study
  3. Propose new strategies on managing liposomal bupivacaine use for possible cost savings

Presenters:

Heather A. Weese, PharmD, BCPS
Director of Pharmacy Operations and Informatics
Community Health Systems Professional Services


Yin Y. Wong, PharmD, BCPS
Health Information and Clinical Outcomes Research Fellow
Wolers Kluwer Health/Community Health Systems Professional Services

This program was approved for 1.0 contact hours of Pharmacy credit through the Belmont University College of Pharmacy. The Belmont University College of Pharmacy is accredited by ACPE (Accreditation Council for Pharmacy Education) as a provider of continuing pharmacy education. UAN: 0863-0000-16-022-L04-P

Download a PDF of this presentation.

Launch Webinar

Go